Afatinib

Gilotrif, Giotrif (afatinib) is a small molecule pharmaceutical. Afatinib was first approved as Gilotrif on 2013-07-12. It is used to treat non-small-cell lung carcinoma and squamous cell carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against epidermal growth factor receptor. In addition, it is known to target receptor tyrosine-protein kinase erbB-2. Gilotrif's patents are valid until 2030-07-05 (FDA).